Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Ascott Sales
White paper
Latest News
PBS reform done with says API
Pharmaceutical wholesaler API says PBS reform has no further to go but new challenges and opportunities abound for medicines distribution.
Servier Australia's so-so 2014
Servier's Australian operation has reported a small drop in profit for the 2014 financial year even though its consolidated revenue went up to $114.3 million.
Roche, Novartis sales up, profit down
Cost cutting may be the order of the day as Swiss pharmas Roche and Novartis both report 2014 sales were up but profits down by significant margins.
Capital boost for mdBriefCase
Online medical education provider mdBriefCase Group has received a "significant investment" from private equity firm Persistence Capital Partners to expand its business.
Call to end CPA-based med reviews
The PSA is calling for the removal of Home Medication Reviews and Residential Medication Management Reviews from the Sixth Community Pharmacy Agreement and recognition of pharmacists as providers under the MBS.
New top ten shows a year of change
The list of top ten originator companies for 2014 shows how much things have changed since last year, not just in the league table but in the amount of PBS benefits flowing to the top group.
Senior staff changes for MNZ, MA
Medicines New Zealand has appointed Dr Graeme Jarvis as its new General Manager while Medicine's Australia's Michael Cook is moving on.
Patent losses still hurting Pfizer
Pfizer has reported a fall in revenue of four per cent for 2014 due to generic competition for key products, and it is predicting more of the same for this year.
BMS' revenue down, Amgen's up
BMS has reported full year revenue for 2014 fell three per cent to US$15.8 billion, while Amgen's revenue of US$20 billion is up seven per cent from 2013.
LNP rules out pharmacy changes
On the eve of the Queensland election, Health Minister Lawrence Springborg has assured the Pharmacy Guild that if re-elected, the LNP will not change pharmacy regulation.
PBAC's QALY focus stalls access
Reliance on Quality Adjusted Life Years to decide on drug reimbursement means fewer new cancer drugs are being funded, reimbursement takes longer and adoption is slower, a new IMS study has found.
Otsuka gets serious about Australia
Japan's Otsuka Pharmaceutical has demonstrated its faith in the future of Australian pharma by committing to an official presence here with a strong emphasis on CNS drugs.
Generic suspensions loom again
The TGA is considering the implications of the EMA's decision to recommend more than 700 generic medicines be suspended because of approvals based on 'flawed' evidence.
Aust middling for CTs: Quintiles boss
Quintiles global CEO, Tom Pike, says Australia is somewhere 'in the middle' in terms of being an attractive destination for clinical trials, and while reforms so far have 'delivered some value', there is still a way to go.
Govt renews $250m vax commitment
The government has renewed its financial commitment to GAVI, the international vaccine alliance, pledging $250m over five years to provide vaccines to children in disadvantaged countries.
Increased backing for pharmacists in primary care roles
Pharmacists appear to be winning more backing for an expanded role in primary care from both a prominent think tank and the public.
Chemo spend surging at 60% a year
PBS spending on chemotherapy is growing at over 60 per cent a year, six times faster than other special programs on the PBS and more than 16 times faster than section 85 drugs.
PBS closes in on $10bn but...
Calendar 2014 saw PBS spending rise to $9.93 billion, $1.6 billion (20%) more than 2013 but the additional spend was driven by a big increase scripts processed, meaning average script cost actually fell over the 12 months.
Advisors warn against TGA changes
A 'robust and independent' regulator is of 'absolute importance', particularly in ensuring that the Australian context for approvals is taken into account, says the TGA's committee of independent clinical experts.
FDA, EMA not perfect docs say
The majority of Royal Colleges and the Australian Medical Association are keen to see the TGA retained as an independent regulator, arguing that its processes ensure public safety and quality use of medicines.
Link INN harmony to other reforms
Despite strongly supporting harmonisation of medicine ingredient names, the pharma industry has told the TGA it wants a business-as-usual approach to their reform.
Call for high cost drugs review
It's time to re-examine how the PBAC makes decisions on high cost drugs and question the multiplicity of PBS programs under which they are funded says a new parliamentary research paper.
Companies split on how much red tape to untie
Pharma companies are looking to the government's review of medicines regulation to open up new pathways for drug approvals but not all favor automatic adoption of overseas decisions.
Don't dump TGA expertise: GMiA
Maintaining the TGA's ability to evaluate and regulate medicines should be a key part of any potential changes to the regulation of medicines in Australia, says the GMiA.
Hep C drug demand will triple
Further evidence has emerged from the Inquiry into Hep C in Australia that pent up demand for new hep C treatments is particularly strong and could 'triple or quadruple' treatment levels.
New twist in biosim name game
The TGA has dropped its previously proposed naming convention for biosimilars following new proposals on the international stage.
Gilead will 'go low' on Sovaldi price
Gilead MD Rob Hetherington has told the hep C inquiry his company is prepared to adjust its Sovaldi price 'consistent with the lowest pricing in the developed world' to win reimbursement.
New MD for Sanofi's Genzyme
Genzyme Australia and New Zealand has appointed Andre Turenne as its new managing director following the resignation of Robert Hendriks from the role.
Call for Ventolin to lose OTC status
Young Australians with asthma show a high level of reliever use and low level of preventer use, with GSK's Ventolin the most common medication taken, resulting in calls for it to be returned to prescription-only status.
Rx drugs boosted J&J in 2014
Johnson & Johnson has posted solid full year 2014 sales with prescription pharmaceuticals up 14.9% to US$32.3 billion, driven by new products and growth in immunology, infectious diseases and oncology.
Open Forum
White paper will show how industry sees itself
At the start of each year, Pharma in Focus publishes the results of our annual Industry Trends survey, which reveals what Aussie pharma experienced last year and expects in the year to come. This year's survey white paper takes a new approach.
Exclusive Interview
Pharma changes mean broader role for CROs
In this exclusive interview, Quintiles global CEO Tom Pike discusses the changing role of contract research organisations in partnership with pharma and biotech, big and small.
Pipeline Monitor
Liraglutide recommended for weight loss
Although it has been unable to win a PBS listing for its initial indication in type 2 diabetes, Novo Nordisk's liraglutide has won a recommendation from the EU's CHMP for a new indication in weight loss.
Approvals Action
Lilly joins GLP-1 crew
Eli Lilly has won approval for once-weekly diabetes treatment Trulicity, joining Novo Nordisk and AstraZeneca in having GLP-1 drugs on the Australian register.
Special Report
Cancer drugs at a crossroads
This year will be an important one for the future of cancer drug reimbursement in Australia with a Senate inquiry into the availability of new therapies due to report in March while the PBAC continues to see more and more cancer options submitted for public funding.
Special Report
International pharma on a roll for 2015
After being the gloomiest of all international industry sectors last year, pharma and healthcare executives' business expectations for 2015 have bounced back to earn them the 'most positive' award for 2015.
FREE Content
Events & Conferences
Pharma in Focus Jobs